Evidence map›Paper›PMID 33457328›Full record

ArticleAdvanced biomedical research2020

Evaluating the Effect of Utrogestan on Idiopathic Intrauterine Growth Retardation.

Belgheis Mohammadi, Marzieh Matinfar, Fatemeh Drees, Sheida Shabanian

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced biomedical research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 86% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Belgheis MohammadiDepartment of Gynecology and Obstetrics, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Marzieh MatinfarDepartments of Gynecology and Obstetrics, Student of Research Committee, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Fatemeh DreesDepartment of Epidemiology and Biostatistic, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Sheida ShabanianDepartment of Gynecology and Obstetrics, Shahrekord University of Medical Sciences, Shahrekord, Iran.
Shahrekord University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntrauterine growth factor (IUGR) is one of the most important causes of neonatal mortality. The aim of this study was to evaluate the therapeutic effect of utrogestan on the treatment of IUGR and its complications. MATERIALS AND

methodsIn this clinical trial, 66 pregnant women with idiopathic IUGR embryos were enrolled. Patients in the intervention group, in addition to receiving routine treatment of control group (high-protein diet, resting), took utrogestan capsules (100 mg) twice daily. The primary and secondary outcomes of the disease were recorded in a checklist. Data were analyzed using SPSS 18 using an independent

resultsIn the intervention group, mean neonatal weight (

conclusionUtrogestan was effective as an inexpensive and effective way to treat IUGR and improve pregnancy outcomes.

Indexed as

Fetal growth retardationplacentautrogestan

Identifiers

PMID33457328
PMCPMC7792872
OpenAlexW3090447141

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.